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Abstract
Background: Development of robust, sensitive, and reproducible diagnostic tests for understanding the epidemiology of
neglected tropical diseases is an integral aspect of the success of worldwide control and elimination programs. In the
treatment of onchocerciasis, clinical diagnostics that can function in an elimination scenario are non-existent and
desperately needed. Due to its sensitivity and quantitative reproducibility, liquid chromatography-mass spectrometry (LC-
MS) based metabolomics is a powerful approach to this problem.
Methodology/Principal Findings: Analysis of an African sample set comprised of 73 serum and plasma samples revealed a
set of 14 biomarkers that showed excellent discrimination between Onchocerca volvulus–positive and negative individuals
by multivariate statistical analysis. Application of this biomarker set to an additional sample set from onchocerciasis
endemic areas where long-term ivermectin treatment has been successful revealed that the biomarker set may also
distinguish individuals with worms of compromised viability from those with active infection. Machine learning extended
the utility of the biomarker set from a complex multivariate analysis to a binary format applicable for adaptation to a field-
based diagnostic, validating the use of complex data mining tools applied to infectious disease biomarker discovery and
diagnostic development.
Conclusions/Significance: An LC-MS metabolomics-based diagnostic has the potential to monitor the progression of
onchocerciasis in both endemic and non-endemic geographic areas, as well as provide an essential tool to multinational
programs in the ongoing fight against this neglected tropical disease. Ultimately this technology can be expanded for the
diagnosis of other filarial and/or neglected tropical diseases.
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Introduction
Onchocerciasis, commonly referred to as ‘‘river blindness’’ is
classified by the World Health Organization (WHO) as a
neglected tropical disease, afflicting approximately 37 million
people in Africa, Central and South America and Yemen, with 89
million more at risk [1]. Symptoms of the disease include acute
dermatitis and blindness, the result of which is the loss of 1 million
disability-adjusted life years (DALYs) annually [2]. The causative
agent, the filarial nematode Onchocerca volvulus, is transmitted in its
larval stage between human hosts through the bite of a Simulium
(sp.) black fly. Once these parasites have matured into the adult
form, they can live for approximately 14 years in subcutaneous
nodules within a human host [3]. The drug ivermectin (Mectizan)
has served as the principal means of onchocerciasis control [4],
however, after initially reducing the number of microfilariae,
within a year, the microfilariae return to levels of 20% or higher
than that prior to treatment [5]. The combination of the lack of
effect of annual ivermectin treatment on adult worm survival and
the fecundity of adult females, along with significant fly and
human migration patterns has helped to perpetuate the disease.
In Africa, where onchocerciasis control programs have been in
place since the founding of the Onchocerciasis Control Pro-
gramme in West Africa (OCP, 1974–2002) and are currently being
conducted by the African Programme for Onchocerciasis Control
(APOC, 1995-present), diagnosis is an essential aspect of the
determination of treatment and distribution of medication. In the
Western hemisphere, accurate and robust diagnostics are essential
for attaining the goal of disease elimination. Twice yearly dosage
of ivermectin, through the efforts of the Onchocerciasis Elimina-
tion Program for the Americas (OEPA, 1992-present), has lead to
a minimization of infection to 13 foci within six countries in
Central and South America. Although mass treatment of
onchocerciasis foci in the Western hemisphere is slated to be
suspended in 2012 [6], achieving the goal of elimination is
contingent upon continued surveillance of the disease. However,
proper surveillance is directly dependent on the availability of
robust diagnostic technologies used for infection assessment. This
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being investigated for targeting Wolbachia endosymbiotic bacteria
[7–10] as well as reports of sub-optimal response to ivermectin
treatment [11,12]. In both of these cases an accurate diagnostic is
critical for the analysis of drug efficacy and patient drug response.
Currently, multinational control and elimination programs
primarily rely on various techniques for diagnosis including:
entomological studies of Simulian flies, Ov specific antigen tests,
antibody tests, analysis of microfilariae in skin snips, nodule
palpation and quality of those nodules that can be excised. There
are a number of technical concerns with each technique including:
a lack of sensitivity and reproducibility, invasiveness, and the
inability to distinguish past from present infection or between
filarial diseases [13–15]. A small molecule/metabolite based test
has the potential for reflecting a more accurate picture of infection
status, as it is a comprehensive measure of the effects of
posttranslational modification and regulation. Furthermore, small
molecules are frequently constitutively produced (e.g., excretory-
secretory products), diffuse easily and are inherently non-
immunogenic in vivo, thus avoiding some of the technical
challenges associated with DNA and protein-based diagnostics.
Although adult O. volvulus worms do not reside directly in the
blood, the highly vascularized subcutaneous nodules of the human
host allow for the potential diffusion of adult parasite-derived
compounds into the blood where compounds involved in host
response to infection might also be present. Since the microfilariae
(mf) and third infective larval stage (L3) of the O. volvulus life cycle
do come in contact with the vascular system during vector
transmission, it is additionally possible that some mf or L3
produced compounds might also be localized to this biological
sample. Certainly, as a starting point, the blood matrix serves as an
easy to obtain, chemically complex data rich matrix for metabolite
analysis [16,17].
However, a technical challenge of analyzing a large number of
metabolites stems from the shear size and complexity of the
resulting data set. Initially devised and applied to the analysis of
highly dimensional gene micro-array data, a number of machine
learning approaches have been expanded and used for identifying
patterns of biomarkers resulting from the multidimensional
analysis of genes, proteins, and metabolites that can be linked to
early detection [18], survival prediction [19], and disease
outcomes [20]. Although identification of a single biomarker
‘‘smoking gun’’ is perceived as the ideal scenario, more attention is
being focused on the use of multiple markers for improving overall
diagnostic accuracy [18,21,22] and model stability [23].
Herein, we report a liquid chromatography-mass spectrometry
(LC-MS) based approach to the discovery of a set of molecules
that, in combination, provide a statistically relevant characteristic
of onchocerciasis infection. An initial untargeted analysis was
applied to the profiling of O. volvulus infected and uninfected blood
plasma and serum samples representing a variety of geographic
regions and disease states, including other tropical diseases. This
analysis resulted in a set of statistically significant mass features
identified for their potential as onchocerciasis-specific biomarkers.
Using multivariate statistics and machine learning algorithms,
these metabolic signatures were further evaluated for their ability
to discriminate O. volvulus-infected and uninfected individuals,
therefore, creating the basis of a small molecule-based diagnostic
for onchocerciasis.
Methods
Ethics statement
The use of human serum and plasma samples in the study was
approved by the Scripps Health Human Subjects Committee.
Samples with geographic origins outside of the United States of
America (USA) consisted of pre-existing, unidentifiable diagnostic
specimens collected with written informed consent and in cases of
illiteracy, a literate witness signed and a thumbprint was made by
the participant. These samples were determined by the Scripps
Health institutional review board (IRB) to be exempt from formal
review under 45 CFR 46 101. O. volvulus negative controls from the
USA consisted of serum and plasma samples and were obtained
with written informed consent from healthy donors through The
Scripps Research Institute Normal Blood Donor Service and
approved by the Scripps Health IRB. All patient codes have been
removed in this publication.
Diagnostic sample origin
Onchocerciasis positive samples were collected in characterized
endemic areas and their status confirmed by either positive skin
snip (mf +) or nodule palpation (nodule +). Several sample groups
used in this analysis were collected during previously published
studies including serum from Liberia [24,25] and Ghana collected
in 2003 [9]. The Ghana sera collected in 1986 and 1991 were
obtained from the College of Public Health, University of South
Florida. Cameroon samples were obtained as part of a
nodulectomy campaign conducted in villages surrounding Kumba,
Cameroon in 2006 and consist of plasma from O. volvulus-positive
individuals (nodule + with nodules containing live females), O.
volvulus-negative individuals (skin snip - volunteers with no current
or prior symptoms of O. volvulus infection), and ambiguous samples
(nodules contained either dead, calcified worms or lipomas with no
evidence of worms, or for which there were no particular disease
symptoms recorded). Guatemala sera were obtained as part of a
nodulectomy campaign conducted by the Guatemala Ministry of
Health and the Centro de Estudios en Salud, Universidad del
Valle de Guatemala in several villages within the Guatemalan
Central Endemic Zone from 2007–2008. Nodules were surgically
removed from all individuals sampled, and nodule dissection was
Author Summary
Onchocerciasis, caused by the filarial parasite Onchocerca
volvulus, afflicts millions of people, causing such debilitat-
ing symptoms as blindness and acute dermatitis. There are
no accurate, sensitive means of diagnosing O. volvulus
infection. Clinical diagnostics are desperately needed in
order to achieve the goals of controlling and eliminating
onchocerciasis and neglected tropical diseases in general.
In this study, a metabolomics approach is introduced for
the discovery of small molecule biomarkers that can be
used to diagnose O. volvulus infection. Blood samples from
O. volvulus infected and uninfected individuals from
different geographic regions were compared using liquid
chromatography separation and mass spectrometry iden-
tification. Thousands of chromatographic mass features
were statistically compared to discover 14 mass features
that were significantly different between infected and
uninfected individuals. Multivariate statistical analysis and
machine learning algorithms demonstrated how these
biomarkers could be used to differentiate between
infected and uninfected individuals and indicate that the
diagnostic may even be sensitive enough to assess the
viability of worms. This study suggests a future potential of
these biomarkers for use in a field-based onchocerciasis
diagnostic and how such an approach could be expanded
for the development of diagnostics for other neglected
tropical diseases.
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individuals whose serum was analyzed in this study. Of those
dissected, no live worms were found. Leishmaniasis positive,
Chagas disease positive, and onchocerciasis negative sera were
obtained from the Centro de Estudios en Salud, Universidad del
Valle de Guatemala. Indian lymphatic filariasis positive plasma
samples were obtained from the Laboratory of Parasitic Diseases,
U.S. National Institutes of Health. A detailed summary of the
samples analyzed in this study is presented in Table 1.
Sample preparation and metabolite extraction
Solvents used were of high performance (HPLC) grade. A
methanol precipitation of proteins was conducted by adding
400 ml aliquots of ice cold methanol to 100 ml aliquots of serum
and plasma samples. The samples were immediately vortexed for
30 sec and allowed to rest on ice for 20 min. After centrifugation
at 13,7806g for 5 min, the metabolite containing supernatent was
removed from the precipitated protein pellet and transferred to
fresh tubes. The supernatent samples were dried in a GeneVac
EX-2 Evaporation System (GeneVac Inc., Valley Center, New
York, USA) at ambient temperature and then resuspended to a
50 ml volume in water: acetonitrile (95:5), vortexed for 30 sec and
then centrifuged again at 13,7806g for 5 min. After being
transferred to LC vials, samples were stored at 4uC and transferred
to the LC-MS thermostated autosampler (6uC), typically within
48 h of their preparation.
Chromatographic workflow
In order to minimize instrumental drift, sample sequences were
composed of a single injection of each sample in randomized order.
To monitor any potential instrument irreproducibility and to
confirm the absence of sample carry over within the chromato-
graphic run, a mobile phase blank and an external standard were
injected every 24 h throughout the duration of the analysis.
LC-ESI MS analysis
Experiments were performed with an electrospray-ionization
time-of-flight (ESI-TOF) MS (Agilent 1200 LC, TOF 6210,
Agilent Technologies, Santa Clara, CA, USA). Each sample
analysis consisted of an 8 ml injection of extracted sample with
chromatographic separation across a reverse phase C18 column
(Zorbax 300SB C18 Capillary, 3.5 mm, 1 mm6150 mm; Agilent
Technologies, Santa Clara, CA, USA) at a capillary pump flow
rate of 75 ml/min. Mobile phase A was composed of water with
0.1% formic acid, and mobile phase B was acetonitrile with 0.1%
formic acid. Each sample was analyzed over a 60 min run time
with a gradient consisting of a 45 min linear gradient from 5% to
95% B and 15 min isocratic hold at 95% B. Between sample
injections a wash step was used to minimize carry over. It consisted
of a saw-tooth linear gradient beginning with a hold at 95% A for
10 min. Then, linear ramping between 5% and 98% B for
5 minute increments throughout the 35 min wash cycle was
followed by a 20 minute final re-equilibration of the column with
an isocratic hold at 95% A.
Mass spectrometric conditions
Consistent mass accuracy (,2 ppm) was maintained through
the constant infusion (2 ml/min) of reference masses via a second
nebulizer. Data were collected in positive electrospray ionization
(ESI) mode scanning in centroid mode from 75 to 1,100 m/z with
a scan rate of 1.0 spectrum per second in 2 GHz extended
dynamic range. The capillary voltage was 3,500 V; the nebulizer
pressure, drying gas flow and gas temperature were set to 20 psig,
12 l/min and 350uC, respectively.
Table 1. Summary of samples analyzed in this study.
Country
of origin Matrix Number/description Clinical pathology Nodulectomy results
Average
mf per mg
Cameroon Plasma 16 O. volvulus infected Palpable nodule(s) All nodules contained live worms —
a
18 uninfected controls — NA 0
b
1 calcified worm Palpable nodule(s) 1 dead, calcified worm —
2 ambiguous lipoma Palpable nodule(s) Fat deposit —
1 indeterminant infection status — — —
Ghana Serum 15 O. volvulus infected Palpable nodule(s) — 12
c
10 O.volvulus,m f + Acute papular onchodermatitis — +
d
Liberia Serum 10 O. volvulus infected — — 527
e
Guatemala Serum 21 O. volvulus infected Palpable nodule(s) 24% of nodules sampled all worms dead —
17 uninfected controls — NA —
6 Leishmania braziliensis —N A —
6 Leishmania mexicana —N A —
5 Trypanosoma cruzi —N A —
India Plasma 4 Wuchereria bancrofti —N A —
USA Plasma 3 O.volvulus uninfected, no known disease — NA —
Serum 3 O. volvulus uninfected, no known disease — NA —
a— indicates no measurement made.
bno mf were measured in samples collected from four different anatomical locations from the 18 control individuals included in this analysis.
cAverage number of mf measured per patient in original study [9] using two skin snips [49].
dSamples are known to be mf+, but records are not available.
eAverage number of mf collected from six different anatomical locations from the 10 patients included in this analysis.
doi:10.1371/journal.pntd.0000834.t001
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statistical analysis
All mass spectral data was collected in .d format and converted
to .mzData using the Mass Hunter Qualitative Analysis software
version B.03.01 (Agilent Technologies, Santa Clara, CA, USA).
XCMS [26] software was used for peak matching, non-linear
retention time alignment and quantitation of mass spectral ion
intensities across all .mzData mass spectral files. Statistical
comparison of the intensity data was conducted using the XCMS
built in Welch’s t-test. False discovery rate (FDR) analysis was
conducted with the q-value program [27] in R version 2.9.0 [28].
Principal Components Analysis (PCA) was conducted with
Statistica software version 8.0 (StatSoftInc., Tulsa, OK, USA),
machine learning algorithms were implemented using Weka
Explorer version 3.6.0 [29] with 10 fold cross-validation settings.
Compound formula assignment
The molecular formula assignment made for the 10 selected
small molecule biomarkers was conducted through a combination
of LC-MS/MS fragmentation using a quadrupole- TOF MS
(QTOF 6510, Agilent Technologies, Santa Clara, CA, USA) and
sub-2 ppm accurate mass measurements using a Bruker Daltonics
Apex II 7.0 Tesla Fourier transform ion cyclotron (FT-ICR) MS
(Bruker Daltonics., Billerica, MA,USA). For the QTOF analysis
chromatographic conditions were identical to those reported for
the profiling experiment and serum plasma samples from either
the Scripps normal blood or pooled patient samples were used for
the analysis. The average m/z and retention times of each of the
biomarkers obtained through XCMS analysis, were used for
targeted MS/MS analysis with a starting collision-induced
dissociation energy of 20eV. Fragmentation patterns were
analyzed with the Agilent Mass Hunter Qualitative Analysis
software version B.03.01 using the targeted MS/MS and formula
generation algorithms and compared with the MS/MS fragment
data in the METLIN database [30].
The FTMS system was equipped with a custom machined
electrospray source with two nebulizers for dual spray ionization.
The main orthogonal nebulizer was used for LC-eluent, while the
second nebulizer was used to introduce a calibration mixture
containing two compounds (aminoantipyrine at 204.1132 m/z and
quinidine 325.1911 m/z) at 3 mM concentration mixed with 1:10
dilution of Agilent low concentration tune mix. A linear
calibration fit was used in the narrow range to internally calibrate
individual mass spectra. The chromatographic conditions were
identical to those reported for the profiling experiment with an
additional analysis using a smaller i.d. column with the same
stationary phase composition (Zorbax 300SB C18 Capillary,
3.5 mm, 0.3 mm6150 mm; Agilent Technologies, Santa Clara,
CA, USA) at a capillary pump flow rate of 4ml/min. Pooled serum
and plasma samples from either the Scripps normal blood or
patient samples were used for the analysis.
Results
A metabolomic approach was developed to address the need for
improvement of diagnostics in onchocerciasis detection. Profiling
of blood biomarkers is much less invasive than skin snipping or
nodulectomy, and should have the added advantage of increased
sensitivity. Antigen tests have been attempted in the past, however,
the immunogenicity of the proteins has been a consistent deterrent
[31,32]. An advantage of profiling low molecular weight
compounds is that they are typically not immunogenic (i.e.,
M.W. ,1,100 amu) and therefore not subject to such a limitation.
It is important to note that profiling molecules with molecular
weight less than 1,100 amu will also include peptides and/or
protein fragments, expanding the pool of available analytes that
can be detected.
Mass spectrometric biomarker selection
The most important aspect of any clinical analytical study resides
with the quality of the samples used; here representative serum and
plasma samples from a variety of subject populations were
incorporated to minimize the effects of non-relevant metabolic
variation(e.g.,nutrition,sex,age,race)andmagnify thosemetabolic
differences that are not only statistically significant between specific
populations, but relevant in identifying the changes in metabolism
that can be directly attributable to infection.
One of the analytical limitations with an untargeted LC-MS
metabolomics approach is that of inter-sequence reproducibility
(i.e., sample preparation, instrument drift, column and mass
spectral baseline variation) when comparing samples directly
between analytical sequences. Such inter-sequence variability can
introduce shifts in ion intensities that can interfere with the
accuracy of downstream statistical analysis. Therefore, this study
was conducted with single injections of each sample, analyzed in
randomized order consecutively within one analytical sequence
(Figure 1). Due to such analytical constraints, small groups of
representative samples were selected from various sample classes
(e.g., O. volvulus-infected and uninfected individuals from various
geographic regions and individuals infected with other parasitic
diseases). XCMS analysis of the sample mass spectral data files
(n=136) resulted in the measurement of a total of 2,350 mass
features. Testing the overall reproducibility of the analysis, the
coefficient of variation (CV) was found to be 15.9% as calculated
from all mass feature intensity values compared across triplicate
injections of a single plasma sample analyzed throughout the
analytical sequence. This value is comparable to previous studies
of analytical variation within plasma and serum analysis by our
laboratory and consistent with a number of other LC-MS based
metabolomics studies [33,34]. Statistical comparison between all
onchocerciasis positive samples (n=76) and all onchocerciasis
negative samples (n=56), including those infected with other
tropical diseases, by Welch’s t-test resulted in 194 features with a
p,1610
24; with a false discovery rate FDR of 54%. To reduce
the number of potentially erroneous markers and focus on those
mass features with the most potential in distinguishing disease, the
top 35 mass features (p,1610
27) were chosen for more stringent
analysis through assessment of the quality of the resulting extracted
ion chromatograms (EICs) (Figure S1). While XCMS pre-
processing software contains a robust retention time correction
and peak alignment algorithm, an important aspect of this study is
the statistical quantitation of biomarkers, therefore any features
with questionable quantitation, observed as imperfect alignment or
inconsistent peak boundaries across samples were ruled out of
further analysis. Additionally, since several mass features may
redundantly describe one chemical metabolite due to the presence
of in-source fragments, adducts, or multiply charged species and
overlapping retention time. The features were separated into
unique peak groups and representative ions with the highest
overall abundance were included in a subset of 14 features for
further analysis (Table 2). Interestingly, the majority of these
features were detected at lower levels in infected individuals
relative to those without onchocerciasis. Analysis of the selected
biomarkers with MS/MS and FTMS analysis has provided
molecular masses and assigned molecular formulas that could be
used to classify the biomarkers into distinct chemical classes; of the
14 markers identified 10 were small molecules and four were
protein fragments or small peptides.
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biomarkers
Beginning with a subset of the larger sample set, the mass
spectral data for the top 14 candidate biomarkers were
investigated for their ability to discriminate O. volvulus infected
individuals (n=55) from healthy controls (n=18) from the African
serum and plasma samples. PCA of the effect of these 14
biomarkers was used to visualize the variation between these
samples groups (Figure 2A). A distinct clustering of the O. volvulus
infected versus the healthy individuals was observed across the x-
axis of the PCA score plot, implying that principal component 1
(PC1) contained the variance of the data set required to distinguish
these two sample groups. The next greatest amount of variation
within the data set appeared to have little effect on discriminating
infection or even geographic differences, but appears to be more
representative of the heterogeneity present among healthy
controls.
Multi-region multivariate analysis
The top 14 candidate biomarkers were also applied to a larger
sample set comprised of multiple geographic regions including O.
volvulus-infected individuals (n=76) and healthy and disease
controls (n=56). PCA of these 14 biomarkers (Figure 2B) revealed
the inherent complexity encountered when employing a metab-
olite profiling approach to diagnostic development. As with the
initial African samples, there is general clustering of the
onchocerciasis positive individuals with the variance contained in
PC1 having good discriminatory power. The disease and healthy
controls cluster separately from the onchocerciasis positive
individuals, however, there is some overlap between one of the
Chagas disease and two of the leishmaniasis positive individuals.
Interestingly, the lymphatic filariasis samples, infected with the
closely related filarial parasite Wuchereria bancrofti, cleanly cluster
with the healthy controls.
Ideally serum and plasma samples would not be directly
compared against each other as the two matrices have distinct
chromatographic differences (Figure S2). However, given the
nature of onchocerciasis sample banks that have been collected
over the past 20 years, it was important to determine if the
resulting biomarker results would be biased to one biological
sample type over another. Importantly, our results show that the
plasma samples from Cameroon as well as the Indian lymphatic
filariasis plasma samples consistently align as expected with the
multi-region serum sample set in distinguishing onchocerciasis
infected from uninfected individuals.
Guatemala central endemic zone metabolic signature
variability
As evidenced in Figure 2C, there is little clustering of the
Guatemalan individuals initially classified as onchocerciasis
positive; rather there appears to be a continuum of onchocerciasis
disease variation within those samples. However, dissections of
excised nodules at the time of nodulectomy revealed no live
worms, as opposed to the results of the Cameroon samples where
Figure 1. Schematic diagram of the LC-MS based metabolomic workflow. Wherein the multi-region serum and plasma samples are
extracted and analyzed within a single sequence on the ESI-TOF in positive mode. Mass spectral data is preprocessed with XCMS software and
multivariate statistical analysis and machine learning classification algorithms are used to distinguish patterns in the data and provide a binary output
to the classification of samples. ROC curves are used to quantify the relationship between sensitivity and specificity for a given test. Ultimately, this
information can be used in an iterative fashion to interrogate larger datasets and provide necessary diagnostic information to better characterize the
disease status of clinical samples from a variety of geographic regions.
doi:10.1371/journal.pntd.0000834.g001
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worms.
Machine learning algorithm implementation
Although tools such as PCA provide a graphical means of
distinguishing between sample groups, they do not have the ability
to provide a quantitative diagnostic assessment as would be needed
nor are they intended to be used for field applications of an
onchocerciasis diagnostic. Alternatively, machine learning algo-
rithms do provide the necessary binary output, as well as calculate
confidence intervals of a given classification. The mass spectral
intensity values for the onchocerciasis serum and plasma data set
were used as inputs in a collection of machine learning algorithms.
The algorithms were chosen to provide a survey of the various
types of machine learning algorithms that could be used with mass
spectral data in diagnostic assessments, either alone or in
combination in more sophisticated algorithms. Results of this
analysis are summarized in Table 3 where sensitivity (true positive
rate) and specificity (1–false positive rate) are displayed. The
receiver operating characteristic (ROC) areas present a numerical
value description of the relationship between sensitivity and
specificity for a given diagnostic test [35,36]. In the context of a
binary classification problem as presented here, a value of 0.5
indicates there is no discrimination within the test and shows any
result is essentially the same as a random guess, while a value of
1.0 indicates a perfect test prediction. Based upon the data, it is
clear that the inclusion of the Guatemala samples within the
sample analysis dramatically increases the number of reported
false positives, compromising the accuracy of the test overall.
However, it is important to note that within the context of the
Africa sample set, the ROC area approaches, or is equal to, a
perfect test prediction in numerous cases, and in the case of the
functional trees classification tree algorithm, perfect sensitivity and
specificity can be achieved.
Discussion
Metabolomics, or the measurement of all the metabolites
present in an organism, and metabolite profiling, in which a
smaller subset of metabolites are measured, have become
established as useful tools in the ‘‘real-time’’ measurement of
organismal metabolism. For infectious disease, previous metabo-
lomics approaches have included mice challenged with the
protozoan parasites Trypanosoma brucei brucei [37] and Plasmodium
berghei [38], trematode parasites Echinostoma caproni [39] and
Schistosoma mansoni [40] and some viruses [41]. This study
represents the first investigation of a metabolomic approach to
the discovery of biomarkers and creation of a diagnostic test for
identifying and classifying onchocerciasis infection. Through the
use of multivariate statistics and machine learning algorithms, the
potential of metabolomic analysis has been demonstrated for
uncovering biomarkers for specific determination of not only
onchocerciasis infection but holds promise for the diagnosis of
other parasitic diseases. Specifically, this was demonstrated by the
Table 2. Characteristics of the 14 candidate biomarkers.
Compound
Classification p-value RT (min)
XCMS
average m/z
Fold
change
Molecular
formula
MS/MS major fragments
(% abundance)
a
FTMS accurate
mass
Fatty acid/Sterol lipid 6.32610
213 45.7 521.4197 23.36 C32H56O5 111.0451(39.15)
503.4123(29.7)
521.4190
Fatty acid/Sterol lipid 2.06610
211 45.7 469.3872 23.71 C28H52O5 415.357(100)
291.2331(48.57)
469.3888
Sterol lipid 2.16610
211 41.4 425.3611 23.55 C26H48O4 389.3432(100.0)
139.1107(12.8)
425.3625
Protein 3.59610
210 31.6 979.9368 23.99 -
Protein 6.53610
210 31.5 986.2677 25.65 -
Hexacosenoic acid 4.01610
210 50.7 395.3867 22.77 C26H50O2 71.0859(100.0)
57.0709(81.99)
395.3804
Pentacosenoic acid 7.75610
210 49.1 381.3710 22.43 C25H48O2 71.0858(100.0)
57.0719(58.75)
381.3728
Fatty alcohol/aldehyde 2.39610
28 48.5 241.2505 1.54 C16H32O 55.0551(77.61)
83.0877(46.81)
—
b
Fatty acid 1.40610
29 39.0 367.2840 22.28 C22H38O4 331.2649(100.0)
79.0547(33.89)
367.2828
Hydroxy-octadecenoic acid 1.52610
29 46.1 299.2581 22.54 C18H34O3 95.0851(100)
71.0863(82.07)
299.2592
Phosphorylated sphingolipid 4.83610
29 30.0 352.2256 21.55 C16H34NO5P 236.2366(100.0)
184.0694(25.99)
352.2247
Sterol lipid 1.44610
28 45.5 447.3470 22.19 C28H46O4 429.3376(43.06)
411.3276(32.91)
447.3470
Protein 2.05610
28 33.3 966.5938 23.09 -
Protein 5.24610
28 31.7 1086.2922 22.76 -
aFragments collected under a collision-induced dissociation energy of 20 eV.
bFTMS accurate mass was not obtained for this compound. This formula is based on TOF-MS mass accuracy.
Statistical values such as p-value and fold change were determined by XCMS analysis of the O. volvulus + and O. volvulus 2 mass spectral data files. Retention time (RT),
and mass to charge value (m/z), fold change and the direction of overall ion intensity change, represents the average value across all files. Molecular formula and
compound class identifier as determined by MS/MS and FTMS analysis is provided.
doi:10.1371/journal.pntd.0000834.t002
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that were not infected with O. volvulus in the multivariate PCA.
This clustering showed the potential specificity of the biomarkers
for the discrimination of onchocerciasis from other filarial diseases.
Although this analysis consists of only four representative
lymphatic filariasis samples, the distinct clustering of these samples
with uninfected individuals is noteworthy and argues for future
analysis that includes other filarial disease pathogens (e.g., Brugia
malayi, Loa loa).
The 14 candidate biomarkers showed excellent performance in
the African specific sample set with up to 99–100% sensitivity and
specificity when examined with the single machine learning
algorithms. With 99% of onchocerciasis disease prevalence in
Africa [42] and the presence of multiple regions of ongoing
transmission [43], this is the most clear test of the biomarker
strategy.
When applied to a multi-region sample set, the multivariate
PCA of the biomarker analysis resulted in a wide spread of results
across the range of infected and uninfected individuals. This
observation raises several questions regarding the unique epide-
miological challenges of measuring onchocerciasis in the Amer-
icas. In the context of the PCA, the Guatemalan patients did not
classify as expected if nodule presence alone is used as an indicator
of infection. However, nodule presence as a diagnostic is known to
have exceedingly poor sensitivity and specificity. A possible
explanation of this data is that the observed heterogeneity is
related to microfilarial load. Unfortunately, skin snip samples with
mf counts were not collected for the Guatemala sample set.
Nonetheless, if this observed spread of data were correlated with
variation in the presence of the mf, then in a region such as the
Guatemalan Central Endemic Zone (CEZ) where biannual dosage
of ivermectin reaches high coverage levels [44], mf should be
nearly absent and we would expect to see no spread of the data but
rather a distinct cluster with or near the uninfected individuals.
Alternatively, the observation that a quarter of the nodules from
these infected individuals from the Guatemalan CEZ did not
contain living worms, indicates that these biomarkers may be
sensitive to not only the presence, but also the viability of the
infective worms. The results of this PCA are consistent with an
increasing body of evidence that biannual ivermectin treatments,
as are received in the Guatemalan CEZ, have an effect on the
viability of adult female worms and ultimately on the elimination
of parasites [45–47]. Since the Guatemalan O. volvulus positive
samples do not segregate along clear lines with the clinically
confirmed samples from Africa, it is possible that the continuum
seen in the PCA plot reflects a range of infection that could be
correlated qualitatively or quantitatively to the health of the worms
(e.g., live healthy, dying, and dead) in vivo. Given that an individual
with dead or dying worms does not need further treatment in the
context of ivermectin mass drug administration, this finding is
particularly valuable in the context of onchocerciasis elimination
progress. Ideally, a biomarker determination study would involve
independent sample sets for training, validation, and testing. Due
to sample limitations inherent to onchocerciasis and many
neglected tropical diseases in general, we have chosen to use an
approach that trains on the majority of the sample set, and
through the 10-fold cross validation machine learning analyses,
conduct tests on small subsets of the full sample set [48].
In this study, we report only those features detected in positive
ion mode with the highest statistical significance and the most
accurate intensity values by XCMS analysis. Consistent among
these 10 small molecule features is that they are all fatty acids and
related fatty acid derivatives. Further investigations into the
biological roles of these fatty acids and fatty acid sterols in
Figure 2. PCA factor score plots of MS peak intensity values for
the 14 candidate onchocerciasis biomarkers. Mass feature
intensity values were extracted through ESI-TOF+/XCMS analysis of
(A) African blood serum and plasma samples from 55 O. volvulus
infected individuals compared against 18 healthy controls. (B) A sample
set including 76 O. volvulus infected individuals compared against 56 O.
volvulus negative controls (including healthy and those infected with
other tropical diseases). (C) An extraction of only those data points
representing the 21 Guatemala O. volvulus infected individuals
compared against 18 healthy controls. Individual data points are
symbolized using the following code for country of origin and disease
status: ‘‘blue diamond’’=Cameroon Ov2, ‘‘blue circle’’=Guatemala
Ov2, ‘‘blue astrisk’’=Scripps Ov2, ‘‘green circle’’=Leishmaniasis Ov2,
‘‘green square’’=Chagas Ov2, ‘‘green triangle’’=LF Ov2, ‘‘pink
diamond’’=Cameroon Ov+, ‘‘pink circle’’=Guatemala Ov+, ‘‘pink
square’’=Ghana Ov+ (1986, 1991 and 2003 samples), ‘‘pink triangle’’=
Liberia Ov+, ‘‘orange diamond’’=Cameroon Ov?.
doi:10.1371/journal.pntd.0000834.g002
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the down-regulated proteins is of distinct interest, not only in the
development of a diagnostic but also to more clearly understand
the biology of this disease. Almost certainly, other biomarkers
could be discovered and validated simply by altering the
chromatographic (e.g., HILIC) and/or ionization conditions
(e.g., negative mode ESI, APCI). It is possible that additional
markers can be eventually be added to the repertoire of
biomarkers used for onchocerciasis detection, further increasing
assay specificity.
The achievement of the goals of elimination and eradication of
onchocerciasis and of the neglected tropical diseases in general,
ultimately depends upon the ability to measure and track the
progress of disease elimination and recrudescence. Our study
highlights advantages of a metabolomics based diagnostic over
onchocerciasis diagnostics currently implemented including:
sensitivity, reproducibility, invasiveness, and the potential for
multiplexing with biomarkers for other filarial and/or neglected
tropical diseases. Fine calibration of this test in the Western
Hemisphere would require characterized samples from individuals
with confirmed active infection. Unfortunately, these samples are
rapidly becoming a rarity due to the success that has been
achieved by OEPA. Further refinement and validation of this
metabolomic based diagnostic approach calls for an expansion of
the mass spectral analysis with larger sample sets, while inclusion
of a greater demographic representation will allow for further
validation of the test in specific populations (e.g., children, adults,
different genetic backgrounds). Eventually, the optimized bio-
markers can be ported into field-based technologies (e.g., immuno-
chromatographic or micro-fluidic-based tests) for use as a point-of-
care diagnostic, a determinant for the distribution and duration of
treatment, and ultimately for long-term disease surveillance.
Supporting Information
Figure S1 Extracted Ion Chromatograms of the 14 candidate
biomarkers as determined from XCMS analysis of O. volvulus +(2)
and O. volvulus 2(2) mass spectral data files.
Found at: doi:10.1371/journal.pntd.0000834.s001 (0.56 MB TIF)
Figure S2 An overlay of representative serum (2) and plasma
(2) TICs (total ion chromatogram) collected from TSRI normal
blood.
Found at: doi:10.1371/journal.pntd.0000834.s002 (0.05 MB TIF)
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